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In selected patients, mitral valve repair using MitraClip®
(Abbott, USA) is a relatively safe and well-tolerated treat-
ment for significant mitral regurgitation [1–3]. We describe
a 56-year-old female with congenitally corrected transposi-
tion of the great arteries (ccTGA) and dextrocardia (Fig. 1a)
with recurrent episodes of heart failure caused by a combi-
nation of systemic (right) ventricular failure and tricuspid
valve regurgitation (Fig. 1b). ccTGA is a rare congenital
heart defect with discordance at both the atrioventricular
and the ventriculoarterial level. In 20 % of the patients
dextrocardia exists. Moderate to severe tricuspid valve re-
gurgitation has a clear impact on cardiac prognosis [4].
We performed a percutaneous tricuspid valve repair using
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Fig. 1 Magnetic resonance imaging showing a ccTGA diagnosis. The hypertrabeculated system ventricle is a morphological right ventricle (a).
Echocardiographic images showing severe tricuspid regurgitation pre-MitraClip® (b). Fluoroscopy showing the delivery system and clip. Note the
dextrocardia with apex to the right (c)
MitraClip® in 2014 (off-label use) (Fig. 1c). Six months
after valve clipping, the tricuspid regurgitation was mild
and there was an important reduction in heart failure symp-
toms. Mitral clipping may be feasible in selected patients
with ccTGA. As far as we know, this is the first percuta-
neous tricuspid valve repair using MitraClip® in a patient
with ccTGA and dextrocardia.
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